At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed May 22, 2026 at 16:05 ET
Abivax reported Q1 2026 net loss of €48.5M (vs €52.4M loss in Q1 2025) with operating loss of €56.2M. The press release highlights durable Phase 2 clinical remission data (68% at week 144 on 25mg de-escalation) and €491.6M cash runway into Q4 2027. The company is pre-revenue with a biotech pipeline catalyst, the ABTECT Phase 3 UC maintenance trial top-line results due late Q2 2026 is the near-term binary event.
- Operational loss of €56.2M in Q1 2026 vs €47.2M in Q1 2025
- Net loss of €48.5M vs €52.4M year-over-year (improved by financial gain)
- Cash, cash equivalents and short-term investments of €491.6M as of March 31, 2026
- Cash runway projected into Q4 2027
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access